Merck KGaA takes the long view on troubled pharma biz

Damian Garde

A series of setbacks has made things tough for 's drug development operation, but CEO Karl-Ludwig Kley said the German company remains committed to the -term promise of its wing.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS